New hope for liver cancer: drug combo targets patients who failed immunotherapy
Disease control
Not yet recruiting
This study tests whether adding the experimental drug fostrox to the standard drug lenvatinib can shrink tumors better than lenvatinib alone in people with advanced liver cancer that got worse after immunotherapy. About 80 adults will take pills daily or in cycles until their can…
Phase: PHASE2 • Sponsor: CHA University • Aim: Disease control
Last updated May 14, 2026 12:04 UTC